IDEAYA Biosciences teams with Genentech to test IDE892 with KRAS G12D drug in pancreatic cancer
IDYA•Estimated patient overlap
The companies estimate MTAP deletions and KRAS G12D mutations co-occur in up to about 15% of PDAC patients.
Commercial rights and supply terms
IDEAYA will supply IDE892; each party keeps commercial rights to its compound for monotherapy or combination use.
Clinical collaboration with Genentech
IDEAYA Biosciences entered a clinical collaboration with Genentech to test IDE892 with KRAS G12D inhibitor GDC-7035 (RG6620) in PDAC.
Study targets MTAP-deleted, KRAS G12D-mutant pancreatic cancer
The trial targets patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma; Genentech will sponsor the study under joint governance.
